Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy

We demonstrate the utility of GC over the existing NCCN subclassification for predicting disease outcomes (biochemical recurrence and metastasis) in IR-PCa. We therefore recommend the use of clinicogenomic risk stratification to identify IR-PCa patients who can be treated with DE-IGRT and safely omit combinatorial ADT.

https://ift.tt/2wpmHol